Irritable Bowel Syndrome News

Boehringer Ingelheim has partnered with Quallent Pharmaceuticals to expand access to its Humira biosimilar citrate-free adalimumab-adbm in the United States, according to a company press release.

Patients with irritable bowel syndrome who tested positive for fructan or fructose malabsorption via hydrogen breath testing had nearly two times higher odds of testing positive for the other carbohydrate, according to study results.

In this Healio video exclusive, Jeffrey Roberts, MS, BSc, shares details about World IBS Day, April 19, which aims to raise awareness and support for patients with irritable bowel syndrome with the theme, “Light Up the Sky for IBS.”

During Irritable Bowel Syndrome Awareness Month, an advocacy group launched the #IBSDilemma campaign to focus on the unique challenges that individuals living with this common gastrointestinal disorder may encounter in daily life.

In a Healio video exclusive, Edward V. Loftus Jr., MD, urged gastroenterologists to prioritize identifying food triggers and recommending dietary interventions and behavioral therapy for patients with irritable bowel syndrome.

Treating patients with irritable bowel syndrome can be a challenge for health care providers, as patients with suspected IBS often report a lengthy list of visceral and somatic symptoms that can overwhelm a busy provider.

Results from a 2023 nationwide survey published in Gastroenterology estimated the prevalence of Rome IV irritable bowel syndrome in the U.S. climbing to 6.1% — higher than previous reports of 4.7% to 5.3%.

Adhering to a higher number of healthy lifestyle behaviors, such as not smoking, staying physically active and getting optimal sleep, was significantly associated with lower incidence of irritable bowel syndrome, according to data in Gut.

The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar.